Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5863 in Advanced or Metastatic Solid Tumors
NCT06005493Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Primary completion
- Mar 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of HBM7022 in gastric cancer (GC), gastroesophageal junction cancer, pancreatic ductal adenocarcinoma (PDAC), esophageal adenocarcinoma (EAC), sponsored by AstraZeneca. Started Jul 2023; status: recruiting.
02
Drugs
HBM7022
03
Conditions
gastric cancer (GC)gastroesophageal junction cancerpancreatic ductal adenocarcinoma (PDAC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT06005493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005493.